$RKLB

U.S. Space Force Expands NSSL Vendor Pool To More Than Rocket Builders

The U.S. Space Force expanded the NSSL Phase 3 Lane 1 vendor pool to seven companies, adding Impulse Space and Relativity Federal on July 7. Initial providers were SpaceX, Blue Origin, and ULA in June 2024, with Rocket Lab and Stoke Space added in March 2025. Lane 1 supports lower-risk national security launches; SpaceX has most awarded task orders.

Original reporting
Published Jul 16, 2026, 9:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 16, 2026, 9:05 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$RKLB
Neutral
medium confidence
Mentioned
$RKLB · $STOK
Relevance
4/10
alphai data visualization · based on aviationweek.com
Decision brief

The 30-second read

$RKLBNeutralLow
01

Why it matters

The newest incremental fact is that Impulse Space and Relativity Federal were added as potential Phase 3 Lane 1 providers on July 7, expanding the eligible vendor pool to seven. However, the article does not disclose new task order awards, pricing, or timelines beyond general expectations for first flights and a broader plan to award more Lane 1 task orders by end of fiscal 2026.

02

Market read

For traders, the actionable signal is limited because the article expands eligibility but does not provide new contract award amounts or immediate execution milestones for the newly added providers beyond general first-flight expectations.

03

What to watch

Execution risk dominates: multiple providers are still awaiting first flights or are grounded due to anomalies, so eligibility alone may not change near-term delivery timelines.

Relevance 4/10Novelty 4/10Timing: July 7 announcement of new Phase 3 Lane 1 providers, ahead of additional Lane 1 task orders by end of fiscal 2026

Background

The Space Force’s National Security Space Launch (NSSL) uses a two-prong procurement strategy, with Phase 3 Lane 1 designed to support more risk-tolerant rockets and systems.

Company-level read

Ticker impact

$RKLBNeutralMedium confidence
Context

Rocket Lab is added as a Phase 3 Lane 1 provider in March 2025, with expectations to fly its vehicle for the first time within the next year.

Expected impact

Limited near-term impact; any effect is likely incremental and sentiment-driven.

Evidence & confidence

The article confirms Rocket Lab’s Lane 1 onboarding and a near-term first flight expectation, but the newest July 7 additions are Impulse Space and Relativity, not Rocket Lab.

$STOKNeutralMedium confidence
Context

Stoke Space was added to the Phase 3 Lane 1 pool in March 2025 and expects to fly its vehicle for the first time within the next year.

Expected impact

Low immediate impact; watch for follow-on task order announcements.

Evidence & confidence

The text provides onboarding timing and a first-flight expectation, which are relevant, but it does not disclose new July 2026 contract details for Stoke.

Market effects

Expanding NSSL Lane 1 eligibility increases competitive optionality for national security launch providers, but the article emphasizes that awarded missions have largely concentrated at SpaceX so far.

US defense space procurement remains the primary driver, with new entrants based in California highlighted.

Limited direct global read-through because the procurement is US national security launch-focused.

Counterpoint

Lane 1 onboarding may not translate into near-term revenue because the article provides no contract values and notes missions awarded so far have largely gone to SpaceX.

Key entities

  • Impulse Space

    New Phase 3 Lane 1 provider announced July 7, pairing its Helios kick stage with a medium-lift rocket from an unspecified launch provider.

  • Relativity Federal

    New Phase 3 Lane 1 provider announced July 7, developing the Terran-R heavy-lift partially reusable rocket.

  • SpaceX

    Described as the only operational NSSL partner with most Lane 1 task orders awarded so far.

  • Blue Origin

    New Glenn remains sidelined after a May 28 static-fire explosion, despite being an initial Lane 1 provider.

  • ULA

    Vulcan remains grounded while investigating a solid rocket booster anomaly from USSF-87 on Feb. 12.

Related articles

$STOKMedAI 8/10

Stoke and Biogen report long-term zorevunersen Dravet data

Stoke Therapeutics and Biogen reported long-term data for zorevunersen, an investigational Dravet syndrome therapy, showing sustained seizure reductions and cognitive improvements over four years. The Phase 3 EMPEROR trial has completed enrollment, with data expected in Q3 2027 ahead of a planned U.S. NDA submission.

$RKLBMed

RKLB Stock Rises Overnight Despite Electron Delay — Cathie Wood’s ARK Buy And BofA’s Bullish Call Lift Sentiment

Rocket Lab (RKLB) shares rose 0.3% overnight after ARK Investment Management bought $12.8M worth of stock and Bank of America (BofA) maintained a 'Buy' rating with a $110 price target. Despite a Q2 adjusted loss of $0.08 per share, revenue grew 62% YoY to $234.07M. The company reported a record backlog of $2.36B and secured $437M in new bookings. However, RKLB stock fell 1% on Monday, marking three consecutive months of losses. The company delayed its next Electron mission due to weather conditi

$RKLBMed

Should You Ignore Rocket Lab Stock? Why SpaceX May Be the Better Space Stock Today.

Rocket Lab (RKLB) stock fluctuated in August, ending near its starting price. Despite recent successes, including a $12M Space Force contract and an $8B acquisition, investors seem to favor SpaceX (SPCX), which is up 30% in August. SpaceX leads in rocket launches, payload capacity, and reusable technology, with Starship targeting 10,000 launches annually. Rocket Lab's Neutron rocket is delayed, while SpaceX has multiple space ventures, including Starlink and lunar missions.

$BIIBMedAI 8/10

Biogen Inc.: Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrom

Stoke Therapeutics and Biogen presented long-term data at the 16th European Epilepsy Congress, showing zorevunersen's potential in treating Dravet syndrome. The Phase 1/2a and OLE studies demonstrated durable seizure reductions, cognitive and behavioral improvements, and quality of life enhancements. The Phase 3 EMPEROR study data is expected in Q3 2027, aiming to complete the U.S. NDA submission. Zorevunersen was generally well tolerated, with some patients treated for over 5 years. Dravet synd